COVID vaccine Vaxzevria – benefit/risk ratio at market approval cont’d

As you have seen in the previous topic, the information regarding the use of Vaxzevria in the elderly is exactly the same in the EU and UK SmPCs. In addition, you may wish to read the January 29, 2021 summary of positive opinion (which accompanies any market approval decision in EU). The assessment of the B/R in the elderly can be found on page 2/5 in the paragraph ''What benefits of COVID-19 Vaccine AstraZeneca have been shown in studies?''.